ROUNDUP/ RATING: Fitch senkt Italiens Bonitätsnote nicht - Herabstufung droht

Burzynski Research Institute, Inc. Announces Publications Documenting Long-term Survival in Malignant Brain Tumors Following Antineoplaston Therapy

Montag, 26.10.2015 23:05 von PR Newswire

PR Newswire

HOUSTON, Oct. 26, 2015 /PRNewswire/ -- Burzynski Research Institute, Inc. (BRI) announced today the publication of two articles in the peer-reviewed literature that document long-term survival in patients with a high-grade glioma (HGG) following Antineoplaston therapy (ANP). Following standard therapy, HGGs have a very poor prognosis. A meta-analysis of 575 HGG studies involving 42,332 patients showed median overall survival ranging from 9.89 to 15.45 months depending on the type of adjuvant chemotherapy employed [Leonard A, et al. J. Neuro Oncol 2012 Jun; 14(Suppl 1): 156-168. doi: 10.1093/neuonc/nos12].   

Dr. S. R. Burzynski and associates describe a patient with a pediatric anaplastic astrocytoma who has an overall survival (OS) and a progression-free survival (PFS) of over 21 years. The only treatment the patient received was IV ANP, which produced a complete response, and subsequent oral ANP. The patient has a good quality of life and suffers no chronic adverse effects of therapy [Burzynski, SR, et al. J Neurol Stroke 2015 Sept; 2(6)]. In addition, Dr. S. R. Burzynski and associates describe more than 11 years OS and PFS in a patient who presented with recurrent glioblastoma multiforme (RGBM) after standard treatment and remains alive, well, and free-of-disease after IV ANP [Burzynski, SR, et al. Cancer Clin Oncol 2015 Oct; 4(2): 41-52]. Using a next-generation-sequencing based assay of 343 cancer-related genes and introns, comprehensive genetic profiling of tumor tissue obtained from this patient was performed 11 years after diagnosis and permitted assignment of this RGBM to the classical subgroup. Patients with classical RGBM may have a reasonable probability of responding to ANP and experiencing long-term survival. It is proposed that this subgroup of RGBM be enrolled in a genomics-driven clinical trial of IV ANP.     

About Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and phase 2 and 3 clinical trials, particularly in the treatment of brain tumors and other forms of cancer.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and further events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to an ability to use Antineoplastons A10 and AS2-1. Burzynski Research Institute, Inc. does not undertake to update any such forward-looking statements or to publically announce developments or events relating to the matters described herein.

Web site:


To view the original version on PR Newswire, visit:

SOURCE Burzynski Research Institute, Inc.